Literature DB >> 24449096

Ethical considerations for the clinical oncologist in an era of oncology drug shortages.

Reshma Jagsi1, Rebecca Spence, W Kimryn Rathmell, Angela Bradbury, Jeffrey Peppercorn, Stephen Grubbs, Beverly Moy.   

Abstract

Shortages of injectable drugs affect many cancer patients and providers in the U.S. today. Scholars and policymakers have recently begun to devote increased attention to these issues, but only a few tangible resources exist to guide clinical oncologists in developing strategies for dealing with drug shortages on a recurring basis. This article discusses existing information from the scholarly literature, policy analyses, and other relevant sources and seeks to provide practical ethical guidance to the broad audience of oncology professionals who are increasingly confronted with such cases in their practice. We begin by providing a brief overview of the history, causes, and regulatory context of oncology drug shortages in the U.S., followed by a discussion of ethical frameworks that have been proposed in this setting. We conclude with practical recommendations for ethical professional behavior in these increasingly common and challenging situations.

Entities:  

Keywords:  Drug; Ethics; Oncology; Policy; Recommendations; Shortage

Mesh:

Substances:

Year:  2014        PMID: 24449096      PMCID: PMC3926786          DOI: 10.1634/theoncologist.2013-0301

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  26 in total

1.  Lasker Clinical Medicine Research Award. Medical dilemmas: the old is new.

Authors:  Belding H Scribner
Journal:  Nat Med       Date:  2002-10       Impact factor: 53.440

2.  Real-time rationing of scarce resources: the Northeast Proton Therapy Center experience.

Authors:  Reshma Jagsi; Thomas F DeLaney; Karen Donelan; Nancy J Tarbell
Journal:  J Clin Oncol       Date:  2004-06-01       Impact factor: 44.544

3.  ASHP Guidelines on Managing Drug Product Shortages in Hospitals and Health Systems.

Authors:  Erin R Fox; Annette Birt; Ken B James; Heather Kokko; Sandra Salverson; Donna L Soflin
Journal:  Am J Health Syst Pharm       Date:  2009-08-01       Impact factor: 2.637

4.  Clinical loyalties and the social purposes of medicine.

Authors:  M G Bloche
Journal:  JAMA       Date:  1999-01-20       Impact factor: 56.272

5.  Investigators seek to increase taxol supply.

Authors:  E Blume
Journal:  J Natl Cancer Inst       Date:  1989-08-02       Impact factor: 13.506

6.  The drugs stop here: a public health framework to address the drug shortage crisis.

Authors:  Sharona Hoffman
Journal:  Food Drug Law J       Date:  2012       Impact factor: 0.619

7.  Responding to the immunoglobulin shortage: a case study.

Authors:  Ann Boulis; Susan Goold; Peter A Ubel
Journal:  J Health Polit Policy Law       Date:  2002-12       Impact factor: 2.265

8.  The ethics of accountability in managed care reform.

Authors:  N Daniels; J Sabin
Journal:  Health Aff (Millwood)       Date:  1998 Sep-Oct       Impact factor: 6.301

9.  The unbearable rightness of bedside rationing. Physician duties in a climate of cost containment.

Authors:  P A Ubel; R M Arnold
Journal:  Arch Intern Med       Date:  1995-09-25

10.  Pandemic influenza preparedness: an ethical framework to guide decision-making.

Authors:  Alison K Thompson; Karen Faith; Jennifer L Gibson; Ross E G Upshur
Journal:  BMC Med Ethics       Date:  2006-12-04       Impact factor: 2.652

View more
  5 in total

1.  The case for an essential medicines list for Canada.

Authors:  Gina Eom; Paul Grootendorst; Jacalyn Duffin
Journal:  CMAJ       Date:  2016-06-13       Impact factor: 8.262

Review 2.  Future cancer research priorities in the USA: a Lancet Oncology Commission.

Authors:  Elizabeth M Jaffee; Chi Van Dang; David B Agus; Brian M Alexander; Kenneth C Anderson; Alan Ashworth; Anna D Barker; Roshan Bastani; Sangeeta Bhatia; Jeffrey A Bluestone; Otis Brawley; Atul J Butte; Daniel G Coit; Nancy E Davidson; Mark Davis; Ronald A DePinho; Robert B Diasio; Giulio Draetta; A Lindsay Frazier; Andrew Futreal; Sam S Gambhir; Patricia A Ganz; Levi Garraway; Stanton Gerson; Sumit Gupta; James Heath; Ruth I Hoffman; Cliff Hudis; Chanita Hughes-Halbert; Ramy Ibrahim; Hossein Jadvar; Brian Kavanagh; Rick Kittles; Quynh-Thu Le; Scott M Lippman; David Mankoff; Elaine R Mardis; Deborah K Mayer; Kelly McMasters; Neal J Meropol; Beverly Mitchell; Peter Naredi; Dean Ornish; Timothy M Pawlik; Jeffrey Peppercorn; Martin G Pomper; Derek Raghavan; Christine Ritchie; Sally W Schwarz; Richard Sullivan; Richard Wahl; Jedd D Wolchok; Sandra L Wong; Alfred Yung
Journal:  Lancet Oncol       Date:  2017-10-31       Impact factor: 41.316

3.  Community Pharmacy Staff Knowledge, Opinion and Practice toward Drug Shortages in Saudi Arabia.

Authors:  Mona Y Alsheikh; Maram A Alzahrani; Norah A Alsharif; Hadeel M Altowairqi; Shahad A Asiri; Bushra M Althubaiti; Ali M Alshahrani; Ahmed I Fathelrahman; Moudi M Alasmari; Amal F Alotaibi
Journal:  Saudi Pharm J       Date:  2021-09-20       Impact factor: 4.330

Review 4.  Cancer Care in the Wake of a Cyberattack: How to Prepare and What to Expect.

Authors:  Steven Ades; Diego Adrianzen Herrera; Tim Lahey; Alissa A Thomas; Sakshi Jasra; Maura Barry; Julian Sprague; Kim Dittus; Timothy B Plante; Jamie Kelly; Peter A Kaufman; Farrah Khan; Cory J Hammond; Kelly Gernander; Polly Parsons; Chris Holmes
Journal:  JCO Oncol Pract       Date:  2021-08-02

Review 5.  Development of biosimilars in an era of oncologic drug shortages.

Authors:  Edward Li; Janakiraman Subramanian; Scott Anderson; Dolca Thomas; Jason McKinley; Ira A Jacobs
Journal:  Drug Des Devel Ther       Date:  2015-06-24       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.